Download Free Sample Report

The global Drugs for Treating Mental Disorders market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The USA market for Global Drugs for Treating Mental Disorders market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

The China market for Global Drugs for Treating Mental Disorders market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

The Europe market for Global Drugs for Treating Mental Disorders market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

This report aims to provide a comprehensive presentation of the global market for Drugs for Treating Mental Disorders, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Treating Mental Disorders.

This report contains market size and forecasts of Drugs for Treating Mental Disorders in global, including the following market information:

• Global Drugs for Treating Mental Disorders Market Revenue, 2018-2023, 2024-2030, ($ millions)
• Global top five companies in 2022 (%)

The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Tablets Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Drugs for Treating Mental Disorders include Johnson and Johnson, Pfizer, Eli Lilly, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, Teva Pharmaceutical, Dr. Reddy's Laboratories and Apotex Inc., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Drugs for Treating Mental Disorders companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drugs for Treating Mental Disorders Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Drugs for Treating Mental Disorders Market Segment Percentages, by Type, 2022 (%)

• Tablets
• Capsule
• Injection
• Solution
• Other

Global Drugs for Treating Mental Disorders Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Drugs for Treating Mental Disorders Market Segment Percentages, by Application, 2022 (%)

• Antipsychotics
• Antidepressants
• Antianxiety (Anxiolyitcs)
• Anti-Seizure Medications
• Stimulants
• Cognitive Disorders And Dementia
• Sleep Disorder Treatments
• Substance Abuse Treatments
• Hypnosis And Tranquilizers
• Other

Global Drugs for Treating Mental Disorders Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Drugs for Treating Mental Disorders Market Segment Percentages, By Region and Country, 2022 (%)

• North America (United States, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
• The Middle East and Africa (Middle East, Africa)
• South and Central America (Brazil, Argentina, Rest of SCA)

Competitor Analysis
The report also provides analysis of leading market participants including:

• Key companies Drugs for Treating Mental Disorders revenues in global market, 2018-2023 (estimated), ($ millions)
• Key companies Drugs for Treating Mental Disorders revenues share in global market, 2022 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Johnson and Johnson
• Pfizer
• Eli Lilly
• GlaxoSmithKline
• AstraZeneca
• Bristol-Myers Squibb
• Teva Pharmaceutical
• Dr. Reddy's Laboratories
• Apotex Inc.
• Mylan Pharmaceuticals
• Par Pharmaceutical
• Aurobindo Pharma
• Torrent Pharmaceuticals
• Jubilant Lifesciences
• Sun Pharmaceutical
• Sandoz (Novartis)
• Hansoh Pharmaceutical
• WATSON Pharmaceuticals
• Zhejiang Langhua Pharmaceuticals
• Forest Laboratories
• H.Lundbeck A/S
• Amneal Pharmaceuticals
• Hetero Drugs
• Macleods Pharmaceuticals
• Silarx Pharmacueticals
• Hikma Pharmaceuticals
• Lupin Limited
• Prinston Pharmaceutical
• STI Pharma

Outline of Major Chapters:
Chapter 1: Introduces the definition of Drugs for Treating Mental Disorders, market overview.
Chapter 2: Global Drugs for Treating Mental Disorders market size in revenue.
Chapter 3: Detailed analysis of Drugs for Treating Mental Disorders company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drugs for Treating Mental Disorders in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.